These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2013-003650-24||A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 (Selinexor) in Patients with Advanced Gynaecologic Malignancies||2017-03-22||due-trials|
|Listed as ongoing, but also has a completion date||2013-003668-30||A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients with Recurrent Gliomas||2020-01-23||bad-data|
|Listed as ongoing, but also has a completion date||2014-000920-26||A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) versus Specified Physician’s Choice in Patients ≥ 60 Years Old with Relapsed/Refractory ...||2018-01-08||bad-data|
|Not reported||2014-001240-38||A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Initial or Refractory/Relapsed Richters Transformati...||2016-09-12||due-trials|
|Ongoing||2014-001977-15||A Phase 2b Open-label, Randomized, Two-arm Study comparing high and low doses of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||not-yet-due|
|Other||2015-003594-14||A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)||not-yet-due|
|Listed as ongoing, but also has a completion date||2016-003094-18||A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients with Multiple Myeloma Previously Treated with Lenalidomide, Pomalidomide, Bortezomib, Carfi...||2019-07-26||bad-data|
|Ongoing||2016-003957-14||A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (...||not-yet-due|
|Ongoing||2017-000607-25||An Investigator-Sponsored Randomized Phase III Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer||not-yet-due|
|Ongoing||2020-000821-22||A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients with Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethason...||not-yet-due|
|Ongoing||2020-001411-25||A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection||not-yet-due|